4.88
+0.0096(+0.20%)
Currency In USD
| Previous Close | 4.87 |
| Open | 4.88 |
| Day High | 5 |
| Day Low | 4.88 |
| 52-Week High | 29.28 |
| 52-Week Low | 1.62 |
| Volume | 4,914 |
| Average Volume | 18,545 |
| Market Cap | 9.33M |
| PE | -0.25 |
| EPS | -19.25 |
| Moving Average 50 Days | 4.85 |
| Moving Average 200 Days | 5.13 |
| Change | 0.01 |
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 1:15 PM GMT
ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will particip
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
GlobeNewswire Inc.
Aug 07, 2025 5:08 PM GMT
- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events amongst the first 35 patients completing the trial sugge
Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
GlobeNewswire Inc.
Aug 06, 2025 1:15 PM GMT
ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, announced today that it will repor